Aclarion (ACON) has secured full funding for its pivotal CLARITY trial which is designed to demonstrate Nociscan’s clinical and economic value in spine surgery. Since January 1, 2025, Aclarion has raised nearly $20M in gross proceeds, which fully funds the CLARITY trial. CLARITY is a prospective, randomized, multicenter, clinical trial led by Dr. Nicholas Theodore of Johns Hopkins as principal investigator. The trial aims to validate Nociscan’s ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data demonstrating Nociscan’s potential to drive better surgical outcomes by matching the surgical intervention to the specific discs identified by Nociscan as being a source of pain.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio